Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-07. Numbers and descriptions here follow the published literature rather than marketing material.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
== Interactions with proteins == All the functions of DNA depend on interactions with proteins. These protein interactions can be non-specific, or the protein can bind specifically to a single DNA sequence. Enzymes can also bind to DNA and of these, the polymerases that copy the DNA base sequence in transcription and DNA replication are particularly important.
In computing, a denial-of-service attack (DoS attack) or distributed denial-of-service attack (DDoS attack) is an attempt to make a machine or network resource unavailable to its intended users. Perpetrators of DoS attacks typically target sites or services hosted on high-profile web servers such as banks, credit card payment gateways, and even root nameservers. DoS attacks often leverage internet-connected devices with vulnerable security measures to carry out these large-scale attacks. DoS attacks may not be limited to computer-based methods, as strategic physical attacks against infrastructure can be just as devastating. For example, cutting undersea communication cables may severely cripple some regions and countries with regards to their information warfare ability.
=== Novels === Anecdotes persanes, dédiées au roy (1727 - English translation: Persian Anecdotes, dedicated to the King) Anecdotes, ou Histoire secrette de la maison ottomane (1722 - English translation: Anecdotes, or Secret History of the Ottoman House) Crémentine, reine de Sanga; histoire indienne (1727 - English translation: Creatine, Queen of Sanga: Indian History) Entretiens nocturnes de Mercure et de La Renommée, au jardin des Thuilleries (1714 - English translation: Nocturnal interviews of Mercury and La Renommée in the Tuileries Garden.) Histoire de Jean de Calais, roi de Portugal, ou, La vertu recompensee (1731 - English translation: The History of Jean de Calais, King of Portugal, or Virtue Rewarded) Histoire d'Osman premier du nom, XIXe empereur des Turcs, et de l'impératrice Aphendina Ashada (1734 - English translation: History of Osman, first of the name, XIXth emperor of the Turks, and of the empress Aphendina Ashada) Histoire du comte d’Oxfort, de Miledy d’Herby, d’Eustache de Saint-Pierre et de Beatrix de Guines au siège de la ville de Calais, sous le règne de Philippe de Valois, roi de France & de Navarré, en 1346 & 1347(1765 - English translation: History of the Count of Oxford, of Miledy of Herby, of Eustace of St. Peter and of Beatrix of Guines at the siege of the city of Calais, under the reign of Philip of Valois, King of France and of Navarre, in 1346 and 1347) Histoire secrette de la conqueste de Grenade (1723 - English translation: The secret history of the conquest of Granada) Histoires du comte d'Oxfort, de Miledy d'Herby, d'Eustache de S.
=== Long-term effects === Most of the research studies on the effects of the low-FODMAP diet are short-term, usually lasting about 28 days. When the diet is suddenly changed, the gut microbiota may undergo rapid changes in the short term. The long term stability of the changes in microbiota caused by the low-FODMAP diet and its effects on health are unclear. It is not known if the changes in microbiota are irreversible. Long-term use of low-FODMAP diet may have negative effects because it causes a detrimental impact on the gut microbiota and metabolome. It should only be used for short periods of time and under the advice of a specialist. The true impact of this diet on health is not fully understood. The restriction phase should not last for more than six weeks. A low-FODMAP diet is highly restrictive in various groups of nutrients, can be impractical to follow in the long term, and may add an unnecessary financial burden.
=== Team indiscipline and fair play === In his early years at Arsenal, Wenger was scrutinised for the club's poor disciplinary record; Winter in 2003 described it as "little short of a crime-wave", while chairman Peter Hill-Wood admitted the players' conduct was unacceptable. Between September 1996 and February 2014, the team received 100 red cards. Wenger has often tried to defend his players, involved in controversial incidents on the field, by saying that he has not seen the incident; this is an option he resorts to when there is no "rational explanation" to defend him, and that he has the player's best interests in mind. However, in both 2004 and 2005, Arsenal topped the Premier League's Fair Play League tables for sporting behaviour and finished second in 2006. Their record as one of the most sporting clubs in the division continued up to 2009, where the team featured in the top four of the Fair Play table. Wenger's team again topped the fair play table for the 2009–10 season. In February 1999, Wenger offered Sheffield United a replay of their FA Cup fifth round match immediately after the match had finished, due to the controversial circumstances in which it was won. The decisive goal was scored by Overmars after Kanu failed to return the ball to the opposition; it was kicked into touch to allow Sheffield United's Lee Morris to receive treatment for an injury. Arsenal went on to win the replayed match 2–1.
Sources: en.wikipedia.org
The 2014 State Department's annual Trafficking in Persons (TIP) report appeared to classify the Khobragade incident as an example of human trafficking, stating: "An Indian consular officer at the New York consulate was indicted in December 2013 for visa fraud related to her alleged exploitation of an Indian domestic worker." In response, India has shown no urgency to allow visits to India by the newly appointed US anti-human trafficking ambassador Susan P. Coppedge and the US special envoy for LGBT rights Randy Berry. Under Section 377 of the Indian Penal Code homosexuality was illegal in India. Indian Ambassador to the US, Arun K. Singh reiterated India's commitment to work within an international framework to tackle the problem of trafficking but rejected any "unilateral assessments" by another country saying "We will never accept it" and downplayed the importance of the visits: "When you ask a U.S. official when somebody will be given a visa, they always say 'we will assess when visa is applied for.' ... I can do no better than to reiterate the U.S. position." In February 2016, the Obama administration notified the US Congress that it intended to provide Pakistan eight nuclear-capable F-16 fighters and assorted military goods including eight AN/APG-68(V)9 airborne radars and eight ALQ-211(V)9 electronic warfare suites despite strong reservations from US lawmakers regarding the transfer of any nuclear weapons capable platforms to Pakistan. Shashi Tharoor, an elected representative from the Congress party in India, questioned the substance of India–U.S.
== Research == Beyond acute promyelocytic leukemia (APL), research is exploring arsenic trioxide’s antitumor effects in solid tumors such as glioma, where it induces cancer cell death by regulating apoptosis and autophagy, promoting oxidative stress within tumor cells, and inhibiting tumor stem cells.
An antagonist is a chemical that acts within the body to reduce the physiological activity of another chemical substance (such as an opiate); especially one that opposes the action on the nervous system of a drug or a substance occurring naturally in the body by combining with and blocking its nervous receptor. There are two main types of antagonist: direct-acting Antagonist and indirect-acting Antagonists:
==== Binding RuBP ==== Carbamylation of the ε-amino group of Lys210 is stabilized by coordination with the Mg2+. This reaction involves binding of the carboxylate termini of Asp203 and Glu204 to the Mg2+ ion. The substrate RuBP binds Mg2+ displacing two of the three aquo ligands.
Sources: en.wikipedia.org
=== Medicine === In medicine, modern biotechnology has many applications in areas such as pharmaceutical drug discoveries and production, pharmacogenomics, and genetic testing (or genetic screening). In 2021, nearly 40% of the total company value of pharmaceutical biotech companies worldwide were active in Oncology with Neurology and Rare Diseases being the other two big applications.
Commercial airliners typically cruise at altitudes of 9–12 km (30,000–39,000 ft) which is in the lower reaches of the stratosphere in temperate latitudes. This optimizes fuel efficiency, mostly due to the low temperatures encountered near the tropopause and low air density, reducing parasitic drag on the airframe. Stated another way, it allows the airliner to fly faster while maintaining lift equal to the weight of the plane. (The fuel consumption depends on the drag, which is related to the lift by the lift-to-drag ratio.) It also allows the airplane to stay above the turbulent weather of the troposphere. The Concorde aircraft cruised at Mach 2 at about 60,000 ft (18 km), and the SR-71 cruised at Mach 3 at 85,000 ft (26 km), all within the stratosphere. Because the temperature in the tropopause and lower stratosphere is largely constant with increasing altitude, very little convection and its resultant turbulence occurs there. Most turbulence at this altitude is caused by variations in the jet stream and other local wind shears, although areas of significant convective activity (thunderstorms) in the troposphere below may produce turbulence as a result of convective overshoot. On October 24, 2014, Alan Eustace became the record holder for reaching the altitude record for a manned balloon at 135,890 ft (41,419 m). Eustace also broke the world records for vertical speed skydiving, reached with a peak velocity of 1,321 km/h (822 mph) and total freefall distance of 123,414 ft (37,617 m), lasting 4 minutes and 27 seconds.
=== Clinical utility === Both in the FAST study, an observational case-control sequencing study including 300 persons from Germany, and in a large sample from the NHANES study, SPINA-GR differed more clearly between subjects with and without diabetes than the corresponding HOMA-IR, HOMA-IS and QUICKI indices.
Other proteins bind to the ends of actin filaments, stabilizing them. These are called "capping proteins" and include CapZ and tropomodulin. CapZ binds the (+) end of a filament, preventing further addition or loss of actin from that end. Tropomodulin binds to a filament's (−) end, again preventing addition or loss of molecule's at that end. Tropomodulin is typically found in cells that require extremely stable actin filaments, such as those in muscle and red blood cells. These actin binding proteins are typically regulated by various cellular signals to control actin assembly dynamics in different cellular locations. Formins, for example, are typically folded in an inactive conformation until they're activated by the binding of the small GTPase Rho. Actin branching at the cell membrane is important for cell movement, and so the plasma membrane lipid PIP2 activates the nucleation promoting factor WASp and inhibits CapZ. WASp is also activated by the small GTPase Cdc42, while another nucleation promoting factor WAVE is activated by the GTPase Rac1.
== Background == The measurement of scattered light from an illuminated sample forms the basis of the so-called classical light scattering measurement. Historically, such measurements were made using a single detector rotated in an arc about the illuminated sample. The first commercial instrument (formally called a "scattered photometer") was the Brice-Phoenix light scattering photometer introduced in the mid-1950s and followed by the Sofica photometer introduced in the late 1960s. Measurements were generally expressed as scattered intensities or scattered irradiance. Since the collection of data was made as the detector was placed at different locations on the arc, each position corresponding to a different scattering angle, the concept of placing a separate detector at each angular location of interest was well understood, though not implemented commercially until the late 1970s. Multiple detectors having different quantum efficiency have different response and hence needs to be normalized in this scheme. An interesting system based upon the use of high speed film was developed by Brunsting and Mullaney in 1974. It permitted the entire range of scattered intensities to be recorded on the film with a subsequent densitometer scan providing the relative scattered intensities. The then-conventional use of a single detector rotated about an illuminated sample with intensities collected at specific angles was called differential light scattering after the quantum mechanical term differential cross section, σ(θ) expressed in milli-barns/steradian.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.